Here, we profiled the proteome of ten body fluids, including ascites, bile, cerebrospinal fluid (CSF), hydrothorax, knee joint fluid (KJF), plasma, saliva, serum, tear, and urine.
Herein, we set out to investigate the responses to first-line therapies (DOS, XELOX, and anti-HER2-based therapies) for GC through a comprehensive proteomic analysis. We constructed a GC cohort that covered three clinical therapy subcohorts, including a DOS subcohort (44 patients treated with DOS th...
Immunotherapy has revolutionized cancer treatment, yet many patients do not respond. Here, we profile the proteome and phosphoproteome of clinical pre-treatment samples from 73 esophageal squamous cell carcinoma (ESCC) patients undergoing anti-programmed death 1 (PD1) immunotherapy.
We reported a comprehensive proteogenomics analysis, including whole-genome sequencing, RNA sequencing, and proteomics and phosphoproteomics profiling, of 448 trace-tumor-samples from 190 urothelial bladder neoplasm patients, covering the whole spectrum of disease stages and grades. DNA damage was a...
Upper tract urothelial carcinoma (UTUC) is often diagnosed late and exhibits poor prognosis. Only limited data are available concerning potential noninvasive biomarkers for disease monitoring. Here, we investigated the proteomic profile of plasma in 362 UTUC patients and 239 healthy control samples....
